Jennifer Pietenpol

Jennifer Pietenpol, PhD
April 5, 2024

Pietenpol to receive ASCO’s highest honor

Jennifer Pietenpol, PhD, will be recognized at the annual meeting of the American Society of Clinical Oncology (ASCO) with one of its highest honors.

By Tom Wilemon
January 29, 2024

Expanded space boosts cutting-edge research in infectious diseases and immunology

The Vanderbilt Institute for Infection, Immunology and Inflammation recently debuted state-of-the-art new facilities in Medical Center.

By Leigh MacMillan
Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
March 22, 2022

VUMC’s Pietenpol, Shyr named AACR Fellows

Vanderbilt’s Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.

By Tom Wilemon
February 17, 2022

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.

By John Howser
February 10, 2022

Pietenpol named chief scientific and strategy officer

Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO).

By John Howser
November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

By Bill Snyder
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
By Leigh MacMillan
July 15, 2021

Susan G. Komen funds VICC breast cancer initiatives

Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.
By Tom Wilemon
September 29, 2020

VICC receives ‘exceptional’ score with renewal as an NCI-Designated Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.
By Tom Wilemon
August 27, 2020

Vanderbilt-Ingram opens cancer center in Wilson County

Vanderbilt-Ingram Cancer Center at Wilson County is slated to open Aug. 31 with a full array of highly specialized services, including diagnostic assessments, medical oncology and radiation oncology.
By Tom Wilemon
July 9, 2020

New space bolsters infectious disease and immunology discovery

The Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) recently moved into its new research and administrative home.
By Leigh MacMillan
1 2 3 … 5